Clinical & Experimental Metastasis

, Volume 21, Issue 3, pp 201–212 | Cite as

Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: Inhibition by gefitinib (`Iressa', ZD1839)

  • Stephen Hiscox
  • Liam Morgan
  • Denise Barrow
  • Carol Dutkowski
  • Alan Wakeling
  • Robert I. Nicholson
Article

Abstract

Despite an initial response to antihormonal therapies, the development of resistance will occur in a significant number of breast cancer patients. The mechanisms that underlie acquired resistance are not yet clear. Using a previously established in vitro cell model of tamoxifen resistance in MCF7 cells, shown to display autocrine epidermal growth factor receptor (EGFR) signalling, we assessed how resistance might modulate their metastatic phenotype in vitro, as metastatic disease is the single most important factor affecting the mortality of cancer patients. Furthermore, we investigated the effect of the EGFR tyrosine kinase inhibitor (EGFR-TKI), gefitinib (`Iressa', ZD1839; AstraZeneca), on this behaviour. The acquisition of tamoxifen resistance in MCF7 cells was accompanied by a dramatic and significant increase in their invasive and motile nature. The affinity of these cells for matrix components was also enhanced. Inhibition of EGFR signalling with gefitinib reduced both basal and TGF-α-stimulated invasion and motility and reduced cell-matrix adhesion. In conclusion, we demonstrate here that resistance to tamoxifen in breast cancer cells is accompanied by a significant increase in their basal motile and invasive activity, properties associated with increased metastatic potential. Inhibition of EGFR signalling by gefitinib significantly inhibited cell motility and invasion thus suggesting a role for the EGF receptor in the aggressive phenotype of tamoxifen-resistant breast cancer cells.

Abbreviations: EGFR – epidermal growth factor receptor; MAPK – mitogen activated protein kinase; TGFα– tumour growth factor α

breast cancer EGFR invasion endocrine resistance motility 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ali S, Coombes RC. Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2002; 2 (2): 101–12.PubMedCrossRefGoogle Scholar
  2. 2.
    Osborne CK, Fuqua SA. Mechanisms of tamoxifen resistance. Breast Cancer Res Treat 1994; 32 (1): 49–55.PubMedCrossRefGoogle Scholar
  3. 3.
    Knowlden JM, Hutcheson IR, Jones HE et al. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 2003; 144 (3): 1032–44.PubMedCrossRefGoogle Scholar
  4. 4.
    Jorissen RN, Walker F, Pouliot N et al. Epidermal growth factor receptor: Mechanisms of activation and signalling. Exp Cell Res 2003; 284 (1): 31–53.PubMedCrossRefGoogle Scholar
  5. 5.
    Hilger RA, Scheulen ME, Strumberg D. The Ras-Raf-MEK-ERK pathway in the treatment of cancer. Onkologie 2002; 25 (6): 511–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Brunet A, Pages G, Pouyssegur J. Constitutively active mutants of MAP kinase kinase (MEK1) induce growth factor-relaxation and oncogenicity when expressed in fibroblasts. Oncogene 1994; 9 (11): 3379–87.PubMedGoogle Scholar
  7. 7.
    Mansour SJ, Matten WT, Hermann AS et al. Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 1994; 265 (5174): 966–70.PubMedGoogle Scholar
  8. 8.
    Oka H, Chatani Y, Hoshino R et al. Constitutive activation of mitogenactivated protein (MAP) kinases in human renal cell carcinoma. Cancer Res 1995; 55 (18): 4182–7.PubMedGoogle Scholar
  9. 9.
    Sivaraman VS, Wang H, Nuovo GJ et al. Hyperexpression of mitogenactivated protein kinase in human breast cancer. J Clin Invest 1997; 99 (7): 1478–83.PubMedCrossRefGoogle Scholar
  10. 10.
    Albanell J, Codony-Servat J, Rojo F et al. Activated extracellular signal-regulated kinases: Association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. Cancer Res 2001; 61 (17): 6500–10.PubMedGoogle Scholar
  11. 11.
    Price DT, Rocca GD, Guo C et al. Activation of extracellular signal-regulated kinase in human prostate cancer. J Urol 1999; 162 (4): 1537–42.PubMedCrossRefGoogle Scholar
  12. 12.
    Price DJ, Avraham S, Feuerstein J et al. The invasive phenotype in HMT-3522 cells requires increased EGF receptor signaling through both PI 3-kinase and ERK 1,2 pathways. Cell Commun Adhes 2002; 9 (2): 87–102.PubMedCrossRefGoogle Scholar
  13. 13.
    Long B, McKibben BM, Lynch M et al. Changes in epidermal growth factor receptor expression and response to ligand associated with acquired tamoxifen resistance or oestrogen independence in the ZR-75-1 human breast cancer cell line. Br J Cancer 1992; 65 (6): 865–9.PubMedGoogle Scholar
  14. 14.
    El-Zarruk AA, van den Berg HW. The anti-proliferative effects of tyrosine kinase inhibitors towards tamoxifen-sensitive and tamoxifenresistant human breast cancer cell lines in relation to the expression of epidermal growth factor receptors (EGF-R) and the inhibition of EGF-R tyrosine kinase. Cancer Lett 1999; 142 (2): 185–93.PubMedCrossRefGoogle Scholar
  15. 15.
    Wells A. EGF receptor. Int J Biochem Cell Biol 1999; 31 (6): 637–43.PubMedCrossRefGoogle Scholar
  16. 16.
    Noonberg SB, Benz CC. Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: Role as anticancer agents. Drugs 2000; 59 (4): 753–67.PubMedCrossRefGoogle Scholar
  17. 17.
    Nicholson RI, McClelland RA, Gee JM et al. Epidermal growth factor receptor expression in breast cancer: Association with response to endocrine therapy. Breast Cancer Res Treat 1994; 29 (1): 117–25.PubMedCrossRefGoogle Scholar
  18. 18.
    Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001; 37 Suppl 4: S9–15.PubMedCrossRefGoogle Scholar
  19. 19.
    Baselga J, Averbuch SD. ZD1839 ('Iressa') as an anticancer agent. Drugs 2000; 60 Suppl 1: 33–40; discussion 41-2.PubMedCrossRefGoogle Scholar
  20. 20.
    Wakeling AE, Guy SP, Woodburn JR et al.ZD1839 (Iressa): An orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002; 62 (20): 5749–54.PubMedGoogle Scholar
  21. 21.
    Hiscox S, Parr C, Nakamura T et al. Inhibition of HGF/SF-induced breast cancer cell motility and invasion by the HGF/SF variant, NK4. Breast Cancer Res Treat 2000; 59 (3): 245–54.PubMedCrossRefGoogle Scholar
  22. 22.
    Fang K, Chen MH. Transfection of anti-sense complementary DNA of human epidermal-growth-factor receptor attenuates the proliferation of human non-small-cell-lung-cancer cells. Int J Cancer 1999; 81 (3): 471–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Maheshwari G, Wiley HS, Lauffenburger DA. Autocrine epidermal growth factor signaling stimulates directionally persistent mammary epithelial cell migration. J Cell Biol 2001; 155 (7): 1123–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Ikegami S, Taguchi T, Ohashi M et al. Aphidicolin prevents mitotic cell division by interfering with the activity of DNA polymerasealpha. Nature 1978; 275 (5679): 458–60.PubMedCrossRefGoogle Scholar
  25. 25.
    Spencer KS, Graus-Porta D, Leng J et al. ErbB2 is necessary for induction of carcinoma cell invasion by ErbB family receptor tyrosine kinases. J Cell Biol 2000; 148 (2): 385–97.PubMedCrossRefGoogle Scholar
  26. 26.
    Kijima T, Maulik G, Ma PC et al. Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells. Cancer Res 2002; 62 (21): 6304–11.PubMedGoogle Scholar
  27. 27.
    Wells A, Kassis J, Solava J et al. Growth factor-induced cell motility in tumor invasion. Acta Oncol 2002; 41 (2): 124–30.PubMedCrossRefGoogle Scholar
  28. 28.
    Ando Y, Jensen PJ. Epidermal growth factor and insulin-like growth factor I enhance keratinocyte migration. J Invest Dermatol 1993; 100 (5): 633–9.PubMedCrossRefGoogle Scholar
  29. 29.
    El-Obeid A, Bongcam-Rudloff E, Sorby M et al. Cell scattering and migration induced by autocrine transforming growth factor alpha in human glioma cells in vitro. Cancer Res 1997; 57 (24): 5598–604.PubMedGoogle Scholar
  30. 30.
    Stoscheck CM, Nanney LB, King LE Jr. Quantitative determination of EGF-R during epidermal wound healing. J Invest Dermatol 1992; 99 (5): 645–9.PubMedCrossRefGoogle Scholar
  31. 31.
    McCawley LJ, O'Brien P, Hudson LG. Overexpression of the epidermal growth factor receptor contributes to enhanced ligand-mediated motility in keratinocyte cell lines. Endocrinology 1997; 138 (1): 121–7. 212 S. Hiscox et al.PubMedCrossRefGoogle Scholar
  32. 32.
    Verbeek BS, Adriaansen-Slot SS, Vroom TM et al. Overexpression of EGFR and c-erbB2 causes enhanced cell migration in human breast cancer cells and NIH3T3 fibroblasts. FEBS Lett 1998; 425 (1): 145–50.PubMedCrossRefGoogle Scholar
  33. 33.
    Fang KS, Ionides E, Oster G et al. Epidermal growth factor receptor relocalization and kinase activity are necessary for directional migration of keratinocytes in DC electric fields. J Cell Sci 1999; 112 (Pt 12): 1967–78.Google Scholar
  34. 34.
    Ware JL. Growth factor network disruption in prostate cancer progression. Cancer Metast Rev 1998; 17 (4): 443–7.CrossRefGoogle Scholar
  35. 35.
    Krueger JS, Keshamouni VG, Atanaskova N et al.Temporal and quantitative regulation of mitogen-activated protein kinase (MAPK) modulates cell motility and invasion. Oncogene 2001; 20 (31): 4209–18.PubMedCrossRefGoogle Scholar
  36. 36.
    Cobb MH, Xu S, Hepler JE et al. Regulation of the MAP kinase cascade. Cell Mol Biol Res 1994; 40 (3): 253–6.PubMedGoogle Scholar
  37. 37.
    Barnes CJ, Bagheri-Yarmand R, Mandal M et al. Suppression of epidermal growth factor receptor, mitogen-activated protein kinase, and Pak1 pathways and invasiveness of human cutaneous squamous cancer cells by the tyrosine kinase inhibitor ZD1839 (Iressa). Mol Cancer Ther 2003; 2 (4): 345–51.PubMedGoogle Scholar
  38. 38.
    Grandis JR, Melhem MF, Gooding WE et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998; 90 (11): 824–32.CrossRefGoogle Scholar
  39. 39.
    Kaufmann AM, Lichtner RB, Schirrmacher V et al. Induction of apoptosis by EGF receptor in rat mammary adenocarcinoma cells coincides with enhanced spontaneous tumour metastasis. Oncogene 1996; 13 (11): 2349–58.PubMedGoogle Scholar
  40. 40.
    Hsieh ET, Shepherd FA, Tsao MS. Co-expression of epidermal growth factor receptor and transforming growth factor-alpha is independent of ras mutations in lung adenocarcinoma. Lung Cancer 2000; 29 (2): 151–7.PubMedCrossRefGoogle Scholar
  41. 41.
    Seth D, Shaw K, Jazayeri J et al. Complex post-transcriptional regulation of EGF-receptor expression by EGF and TGF-alpha in human prostate cancer cells. Br J Cancer 1999; 80 (5-6): 657–69.PubMedCrossRefGoogle Scholar
  42. 42.
    Cai YC, Jiang Z, Vittimberga F et al. Expression of transforming growth factor-alpha and epidermal growth factor receptor in gastrointestinal stromal tumours. Virchows Arch 1999; 435 (2): 112–115.PubMedCrossRefGoogle Scholar
  43. 43.
    Umekita Y, Ohi Y, Sagara Y et al. Co-expression of epidermal growth factor receptor and transforming growth factor-alpha predicts worse prognosis in breast-cancer patients. Int J Cancer 2000; 89 (6): 484–7.PubMedCrossRefGoogle Scholar
  44. 44.
    Pichard V, Honore S, Kovacic H et al. Adhesion, actin cytoskeleton organisation and the spreading of colon adenocarcinoma cells induced by EGF are mediated by alpha2beta1 integrin low clustering through focal adhesion kinase. Histochem Cell Biol 2001; 116 (4): 337–48.PubMedCrossRefGoogle Scholar
  45. 45.
    Yamanaka I, Koizumi M, Baba T et al. Epidermal growth factor increased the expression of alpha2beta1-integrin and modulated integrin-mediated signaling in human cervical adenocarcinoma cells. Exp Cell Res 2003; 286 (2): 165–74.PubMedCrossRefGoogle Scholar
  46. 46.
    Burridge K, Turner CE, Romer LH. Tyrosine phosphorylation of paxillin and pp125FAK accompanies cell adhesion to extracellular matrix: A role in cytoskeletal assembly. J Cell Biol 1992; 119: 893–903.PubMedCrossRefGoogle Scholar
  47. 47.
    Golubovskaya V, Beviglia L, Xu Lh et al. Dual inhibition of focal adhesion kinase and epidermal growth factor receptor pathways cooperatively induces death receptor-mediated apoptosis in human breast cancer cells. J Biol Chem 2002; 277 (41): 38978–87.PubMedCrossRefGoogle Scholar
  48. 48.
    Lu Z, Jiang G, Blume-Jensen P et al. Epidermal growth factor-induced tumor cell invasion and metastasis initiated by dephosphorylation and downregulation of focal adhesion kinase. Mol Cell Biol 2001; 21 (12): 4016–31.PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 2004

Authors and Affiliations

  • Stephen Hiscox
  • Liam Morgan
  • Denise Barrow
  • Carol Dutkowski
  • Alan Wakeling
  • Robert I. Nicholson

There are no affiliations available

Personalised recommendations